PTC Therapeutics Inc. diskutieren
PTC Therapeutics Inc.
WKN: A1W0MW / Symbol: PTCT / Name: PTC Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
31,00 €
4,03 %
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at Cantor Fitzgerald from $75.00 to $73.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $73.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $73.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at Raymond James from an "outperform" rating to an "underperform" rating.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $35.00 to $22.00. They now have a "sell" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at Truist Financial Co. from $60.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at Bank of America Co. from $43.00 to $23.00. They now have an "underperform" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at Citigroup Inc. from a "neutral" rating to a "sell" rating. They now have a $17.00 price target on the stock, down previously from $29.00.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $51.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $37.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $51.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $28.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at Cantor Fitzgerald from $51.00 to $45.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Jefferies Financial Group Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Ford Motor Co. diskutieren